CN106317104A - 2- carbonyl propionic acid p-tert-butyl benzoyl hydrazone stannous phenide complex and preparing method and application thereof - Google Patents
2- carbonyl propionic acid p-tert-butyl benzoyl hydrazone stannous phenide complex and preparing method and application thereof Download PDFInfo
- Publication number
- CN106317104A CN106317104A CN201610712404.2A CN201610712404A CN106317104A CN 106317104 A CN106317104 A CN 106317104A CN 201610712404 A CN201610712404 A CN 201610712404A CN 106317104 A CN106317104 A CN 106317104A
- Authority
- CN
- China
- Prior art keywords
- tert
- propionic acid
- butyl benzoyl
- coordination compound
- stannous phenide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 12
- LBEMTJSPMVHSNV-UHFFFAOYSA-N C(C)(C)(C)C1=CC=C(C(=O)NN=C(C(C)=C=O)O)C=C1 Chemical compound C(C)(C)(C)C1=CC=C(C(=O)NN=C(C(C)=C=O)O)C=C1 LBEMTJSPMVHSNV-UHFFFAOYSA-N 0.000 title abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 60
- -1 tert-butyl benzoyl Chemical group 0.000 claims description 56
- BFGWFADODZRUMH-UHFFFAOYSA-N 2-methyl-3-oxoprop-2-enoic acid Chemical compound O=C=C(C)C(O)=O BFGWFADODZRUMH-UHFFFAOYSA-N 0.000 claims description 45
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 claims description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 20
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 235000010290 biphenyl Nutrition 0.000 claims description 11
- 239000004305 biphenyl Substances 0.000 claims description 11
- 239000013078 crystal Substances 0.000 claims description 11
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 11
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 10
- 238000011275 oncology therapy Methods 0.000 claims description 10
- 238000002425 crystallisation Methods 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- OQVSACGODYLLEZ-UHFFFAOYSA-N n-tert-butylbenzohydrazide Chemical compound CC(C)(C)N(N)C(=O)C1=CC=CC=C1 OQVSACGODYLLEZ-UHFFFAOYSA-N 0.000 claims description 8
- 229940054269 sodium pyruvate Drugs 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 238000000902 119Sn nuclear magnetic resonance spectroscopy Methods 0.000 claims description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 claims description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 6
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 238000002447 crystallographic data Methods 0.000 claims description 5
- 201000005296 lung carcinoma Diseases 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims description 2
- 229910052718 tin Inorganic materials 0.000 claims description 2
- YTZKOQUCBOVLHL-UHFFFAOYSA-N tert-butylbenzene Chemical compound CC(C)(C)C1=CC=CC=C1 YTZKOQUCBOVLHL-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000003963 dichloro group Chemical group Cl* 0.000 claims 1
- 230000005311 nuclear magnetism Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 37
- 230000001093 anti-cancer Effects 0.000 description 13
- 238000011160 research Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 239000002262 Schiff base Substances 0.000 description 3
- 150000004753 Schiff bases Chemical class 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 125000002524 organometallic group Chemical group 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229910020813 Sn-C Inorganic materials 0.000 description 1
- 229910018732 Sn—C Inorganic materials 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- AYOHIQLKSOJJQH-UHFFFAOYSA-N dibutyltin Chemical compound CCCC[Sn]CCCC AYOHIQLKSOJJQH-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- IXSZQYVWNJNRAL-UHFFFAOYSA-N etoxazole Chemical compound CCOC1=CC(C(C)(C)C)=CC=C1C1N=C(C=2C(=CC=CC=2F)F)OC1 IXSZQYVWNJNRAL-UHFFFAOYSA-N 0.000 description 1
- WDQNIWFZKXZFAY-UHFFFAOYSA-M fentin acetate Chemical compound CC([O-])=O.C1=CC=CC=C1[Sn+](C=1C=CC=CC=1)C1=CC=CC=C1 WDQNIWFZKXZFAY-UHFFFAOYSA-M 0.000 description 1
- NJVOZLGKTAPUTQ-UHFFFAOYSA-M fentin chloride Chemical compound C=1C=CC=CC=1[Sn](C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 NJVOZLGKTAPUTQ-UHFFFAOYSA-M 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003606 tin compounds Chemical class 0.000 description 1
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 1
- 229910001887 tin oxide Inorganic materials 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 238000001942 tin-119 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2284—Compounds with one or more Sn-N linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses a 2- carbonyl propionic acid p-tert-butyl benzoyl hydrazone stannous phenide complex in the following structural formula (I) of (img file='dest_path_image002. TIF'wi='362'he='184'/), wherein Ph is phenyl. The invention also discloses the preparing method and application in preparing anti-cancer drugs for 2- carbonyl propionic acid p-tert-butyl benzoyl hydrazone stannous phenide complex.
Description
Technical field
The present invention relates to a kind of 2-carbonyl propionic acid to tert-butyl benzoyl hydrazone stannous phenide coordination compound and preparation method thereof, with
And this 2-carbonyl propionic acid is to the application in preparing cancer therapy drug of the tert-butyl benzoyl hydrazone stannous phenide coordination compound.
Background technology
Organotin is the metallo-organic compound that a class contains Sn-C key.Researcher just noticed before very early
The Anticancer Activity in vitro of organo-tin compound.The research of organotin (IV) antitumor activity of compound can trace back to nineteen twenty-nine.
1967, Kanisawa etc. thought that stannic chloride is invalid to the primary tumor of mice and rat.But in 1972, Brown found,
By food or drug administration by injection, triphenyltin acetate Ph3SnOOCCH3Can suppress the tumor growth of mice, and triphenyltin chloride
Then can not.Between 1972 ~ 1977 years, Holland's substantial amounts of organo-tin compound of scholar's research, but find no further screening valency
The compound of value.They continue deeper into research, finally found that the tin compound of two organic group coordinations, such as tin-oxide
(R2SnO), stannum hydroxide ［ SnR2(OH) X ］ etc. have an anti-tumor activity, and find out that they all contain or hydrolyze and can produce stannum oxygen
Key.1980, Crowe etc. was found that again some organo-tin compounds have preferable active anticancer, from this, resisted about organotin
The research of cancer activity becomes another extremely active focus after cisplatin.1989, American National anticancer research institute
(National Cancer Institute) has carried out antitumor activity screening, result table to more than 2,000 kinds of organo-tin compounds
Brighter organo-tin compounds have inhibitory action to P388 Lymphocytic leukemia.2002, Gielen et al. was to organic
The activity of stannum carboxylate compound has done comprehensive summing up, thinks that many organo-tin compounds have the most external really after research
Active anticancer.
Research shows, the organic group that organotin atom connects and the part participating in coordination decide organo-tin compound
Biological activity, select some itself have good biological activity organic ligand with in organotin tin atom coordination cause
The great interest of people.Acylhydrazone is by a class Schiff compound of hydrazide kind compound modification, they
It is condensed by aldehydes or ketones and hydrazides and forms, molecule has the of bonding similar with peptide bond, there is good biological activity, stronger joining
Capability and various coordination mode, and have a wide range of applications at aspects such as medicine, pesticide, material and analytical reagents.Closely
Nian Lai, it is compared in terms of biological activity by the most many research worker in depth studies, and research finds acylhydrazone class
Compound has the various active such as anticancer, sterilization, antiinflammatory.Therefore, acylhydrazone class Schiff part is combined with organotin, it is intended to
Obtain the noval chemical compound that biological activity is higher, become the research direction that people are interested.
Chinese patent CN 102718794A discloses a kind of double acylhydrazone class Schiff stannous phenide coordination compound and in system
Standby Antilung gland cancer, colon cancer, leukaemia medicine in application.
Chinese patent CN 101851251A disclose a kind of acylhydrazone class Schiff part dibutyl tin coordination compound and
Application in preparation treatment hepatocarcinoma, adenocarcinoma of lung, breast carcinoma, carcinoma of prostate, colon cancer or the youngest leukemic medicine of grain.
Document (Journal of Organometallic Chemistry, 2014,75:83-91) is reported, organotin
Acylhydrazone class Schiff base complex is thin to human colon cancer cell (HCT-116), human lung adenocarcinoma cell (A549), human umblilical vein endothelial
Born of the same parents (HUVEC) have relatively strong biological activity, and are better than carboplatin.
Document (Journal of Organometallic Chemistry, 2013,724:23-31) is reported, series has
Machine stannum acylhydrazone class Schiff base complex, organo-tin compound and acylhydrazone class Schiff part are respectively to human lung adenocarcinoma cell
(A549), the inhibitory action of the cancerous cell such as human colon cancer cell (HCT-8), people in loop (hl-60).
Document (Bioorganic & Medicinal Chemistry Letters, 2015,25:4461-4463)
Report, multiple acylhydrazone class Schiff part is to human liver cancer cell (HuH-7) and the active anticancer of human lung adenocarcinoma cell (A549).
Document (Journal of Organometallic Chemistry, 2016,804:48-58) is reported, two hydrocarbon
Base stannum acylhydrazone class Schiff base complex is to human lung adenocarcinoma cell (A549), human cervical carcinoma cell (HeLa), human breast cancer cell
(MCF-7) inhibitory action of cancerous cell such as.
Being the material that the experiment proved that and have active anticancer based on acylhydrazone class Schiff organotin complex, the present invention selects
Selecting and react tert-butyl benzoyl hydrazine, Sodium Pyruvate under certain condition with diphenyl stannum dichloride, synthesis has obtained people's lung
Cancerous cell (H460), human liver cancer cell (HepG2) and human breast cancer cell (MCF7) have the coordination compound of certain inhibitory activity, for
Exploitation cancer therapy drug provides new approach.
Summary of the invention
The first object of the present invention there is provided a kind of 2-carbonyl propionic acid to tert-butyl benzoyl hydrazone stannous phenide coordination compound.
The second object of the present invention is to provide above-mentioned 2-carbonyl propionic acid to tert-butyl benzoyl hydrazone stannous phenide coordination compound system
Preparation Method.
The third object of the present invention is to provide above-mentioned 2-carbonyl propionic acid and exists tert-butyl benzoyl hydrazone stannous phenide coordination compound
Prepare the application in cancer therapy drug.
As a kind of 2-carbonyl propionic acid of a first aspect of the present invention to tert-butyl benzoyl hydrazone stannous phenide coordination compound, for
The coordination compound of structure formula (I)
(I)
Wherein Ph is phenyl.
The 2-carbonyl propionic acid of the present invention to tert-butyl benzoyl hydrazone stannous phenide coordination compound through elementary analysis, infrared spectrum,
Nuclear magnetic resoance spectrum and X-ray single crystal diffraction structural analysis, result is as follows:
Elementary analysis (C54H60N4O8Sn2): value of calculation: C 57.37, H 5.35, N 4.96；Measured value: C 57.40, H 5.33,
N 4.98。
FT-IR (KBr, ν/cm-1): 3631, 3072, 3055, 2962, 2904, 1689, 1602, 1492,
1479, 1431, 1390, 1363, 1321, 1267, 1203, 1159, 1070, 1001, 921, 848, 769,
723, 690, 594, 557, 543, 493, 453。
1H NMR (500 MHz, CDCl3, δ/ppm): 8.28 (d, J = 8.5 Hz, 2H), 7.81-7.83
(m, 4H), 7.55 (d, J = 8.4 Hz, 2H), 7.44-7.48 (m, 6H), 3.49 (s, 3H), 2.62 (s,
3H), 1.38 (s, 9H), 0.98 (s, 1H)。
13C NMR (126 MHz, CDCl3, δ/ppm): 174.83, 163.89, 158.74, 155.41,
136.15, 135.60, 131.42, 129.37, 129.31, 128.60, 125.54, 50.92, 35.19, 31.15,
13.95。
119Sn NMR (187 MHz, CDCl3, δ/ppm): -293.95。
The 2-carbonyl propionic acid of the present invention is crystal structure to tert-butyl benzoyl hydrazone stannous phenide coordination compound, and its crystal is three
Oblique system, space group P-1, a=1.12390 (4) nm, b=1.16868 (4) nm, c=1.18171 (4) nm, α=
67.6440 (10) °, β=85.4060 (10) °, γ=64.0140 (10) °, Z=1, V=1.28335 (8) nm3, Dc=
1.463 Mg·m-3, m (MoK α)=1.030 mm-1, F (000)=576.
Tert-butyl benzoyl hydrazone stannous phenide coordination compound is structurally characterized in that by the 2-carbonyl propionic acid of the present invention: stannum in molecule
Atom is seven coordination distortion pentagonal bipyramid configurations.
The 2-carbonyl propionic acid of the present invention has certain thermally-stabilised scope to tert-butyl benzoyl hydrazone stannous phenide coordination compound,
Can stable existence below 104 DEG C.
As a kind of 2-carbonyl propionic acid of a second aspect of the present invention to tert-butyl benzoyl hydrazone stannous phenide coordination compound
Preparation method, adds diphenyl stannum dichloride, to tert-butyl benzoyl hydrazine, Sodium Pyruvate in the reaction vessel having nitrogen to protect
And solvent absolute methanol, under conditions of temperature is 45 ~ 75 DEG C, reacts 5 ~ 24 h, cooling, filters, under conditions of 20 ~ 35 DEG C
Control solvent volatilization crystallization, obtain yellow transparent crystal, be 2-carbonyl propionic acid to tert-butyl benzoyl hydrazone stannous phenide coordination compound.
The preparation characteristic of tert-butyl benzoyl hydrazone stannous phenide coordination compound is by the 2-carbonyl propionic acid of the present invention: from letter relatively
The raw material being singly easy to get sets out, and without the separation of intermediate, directly obtains baroque molecule, i.e. one kettle way；Such reaction
Economically and environmentally on close friend advantageously.
In a preferred embodiment of the invention, described diphenyl stannum dichloride, to tert-butyl benzoyl hydrazine, acetone acid
The amount of the material of sodium three is than for 1:(1 ~ 1.05): (1.05 ~ 1.15).
In a preferred embodiment of the invention, described solvent absolute methanol consumption is every mM of diphenyl dichloride
Stannum adds 15 ~ and 35 milliliters.
Tert-butyl benzoyl hydrazone stannous phenide coordination compound is existed by a kind of 2-carbonyl propionic acid as a third aspect of the present invention
Prepare the application in cancer therapy drug.
Applicant has carried out external anticancer work to above-mentioned 2-carbonyl propionic acid to tert-butyl benzoyl hydrazone stannous phenide coordination compound
Property determine research, it is thus identified that 2-carbonyl propionic acid has certain Anti-cancer biologic and lives tert-butyl benzoyl hydrazone stannous phenide coordination compound
Property, say, that the purposes of above-mentioned coordination compound is the application in preparing cancer therapy drug, is exactly to prepare anti-human lung specifically
Application in cancer, people's hepatocarcinoma and human breast carcinoma medicine.
The 2-carbonyl propionic acid of the present invention is thin to human lung carcinoma cell, people's hepatocarcinoma to tert-butyl benzoyl hydrazone stannous phenide coordination compound
Born of the same parents and human breast cancer cell demonstrate good active anticancer, and the 2-carbonyl propionic acid of the present invention is to tert-butyl benzoyl hydrazone diphenyl
The features such as stannum coordination compound active anticancer height, low cost, preparation method are simple, provide new way for developing new cancer therapy drug.
Accompanying drawing explanation
Fig. 1 is the 2-carbonyl propionic acid IR spectrogram to tert-butyl benzoyl hydrazone stannous phenide coordination compound.
Fig. 2 is that 2-carbonyl propionic acid is to tert-butyl benzoyl hydrazone stannous phenide coordination compound1H NMR spectra.
Fig. 3 is that 2-carbonyl propionic acid is to tert-butyl benzoyl hydrazone stannous phenide coordination compound13C NMR spectra.
Fig. 4 is that 2-carbonyl propionic acid is to tert-butyl benzoyl hydrazone stannous phenide coordination compound119Sn NMR spectra.
Fig. 5 is the 2-carbonyl propionic acid crystal structure figure to tert-butyl benzoyl hydrazone stannous phenide coordination compound.
Fig. 6 is the 2-carbonyl propionic acid TG-DTG curve to tert-butyl benzoyl hydrazone stannous phenide coordination compound.
Detailed description of the invention
By detailed description below, the present invention is described in further detail.
Embodiment 1:
The preparation to tert-butyl benzoyl hydrazone stannous phenide coordination compound of the 2-carbonyl propionic acid:
0.344g (1.0mmol) diphenyl stannum dichloride, 0.192g is added in the 100mL there-necked flask having nitrogen to protect
(1.0mmol) to tert-butyl benzoyl hydrazine, 0.121g (1.1mmol) Sodium Pyruvate and 15mL solvent absolute methanol, in temperature it is
8 h are reacted under conditions of 45 ~ 75 DEG C, cooling, filter, under conditions of 20 ~ 35 DEG C, control solvent volatilization crystallization, obtain yellow transparent
Crystal, is 2-carbonyl propionic acid to tert-butyl benzoyl hydrazone stannous phenide coordination compound.Productivity: 84.4%.Fusing point: 104 ~ 106 DEG C
(dec)。
Elementary analysis (C54H60N4O8Sn2): value of calculation: C 57.37, H 5.35, N 4.96；Measured value: C 57.40, H
5.33, N 4.98.
FT-IR (KBr, ν/cm-1): 3631, 3072, 3055, 2962, 2904, 1689, 1602, 1492,
1479, 1431, 1390, 1363, 1321, 1267, 1203, 1159, 1070, 1001, 921, 848, 769,
723, 690, 594, 557, 543, 493, 453。
1H NMR (500 MHz, CDCl3, δ/ppm): 8.28 (d, J = 8.5 Hz, 2H), 7.81-7.83
(m, 4H), 7.55 (d, J = 8.4 Hz, 2H), 7.44-7.48 (m, 6H), 3.49 (s, 3H), 2.62 (s,
3H), 1.38 (s, 9H), 0.98 (s, 1H)。
13C NMR (126 MHz, CDCl3, δ/ppm): 174.83, 163.89, 158.74, 155.41,
136.15, 135.60, 131.42, 129.37, 129.31, 128.60, 125.54, 50.92, 35.19, 31.15,
13.95。
119Sn NMR (187 MHz, CDCl3, δ/ppm): -293.95。
Crystallographic data: anorthic system, space group P-1, a=1.12390 (4) nm, b=1.16868 (4) nm, c=
1.18171 (4) nm, α=67.6440 (10) °, β=85.4060 (10) °, γ=64.0140 (10) °, Z=1, V=
1.28335(8) nm3, Dc=1.463 Mg m-3, m (MoK α)=1.030 mm-1, F (000)=576.
Embodiment 2:
The preparation to tert-butyl benzoyl hydrazone stannous phenide coordination compound of the 2-carbonyl propionic acid:
0.344g (1.0mmol) diphenyl stannum dichloride, 0.192g is added in the 100mL there-necked flask having nitrogen to protect
(1.0mmol) to tert-butyl benzoyl hydrazine, 0.115g (1.05mmol) Sodium Pyruvate and 35mL solvent absolute methanol, in temperature
5 h are reacted under conditions of being 45 ~ 75 DEG C, cooling, filter, under conditions of 20 ~ 35 DEG C, control solvent volatilization crystallization, obtain yellow saturating
Bright crystal, is 2-carbonyl propionic acid to tert-butyl benzoyl hydrazone stannous phenide coordination compound.Productivity: 87.3%.Fusing point: 104 ~ 106 DEG C
(dec)。
Elementary analysis (C54H60N4O8Sn2): value of calculation: C 57.37, H 5.35, N 4.96；Measured value: C 57.40, H
5.33, N 4.98.
FT-IR (KBr, ν/cm-1): 3631, 3072, 3055, 2962, 2904, 1689, 1602, 1492,
1479, 1431, 1390, 1363, 1321, 1267, 1203, 1159, 1070, 1001, 921, 848, 769,
723, 690, 594, 557, 543, 493, 453。
1H NMR (500 MHz, CDCl3, δ/ppm): 8.28 (d, J = 8.5 Hz, 2H), 7.81-7.83
(m, 4H), 7.55 (d, J = 8.4 Hz, 2H), 7.44-7.48 (m, 6H), 3.49 (s, 3H), 2.62 (s,
3H), 1.38 (s, 9H), 0.98 (s, 1H)。
13C NMR (126 MHz, CDCl3, δ/ppm): 174.83, 163.89, 158.74, 155.41,
136.15, 135.60, 131.42, 129.37, 129.31, 128.60, 125.54, 50.92, 35.19, 31.15,
13.95。
119Sn NMR (187 MHz, CDCl3, δ/ppm): -293.95。
Crystallographic data: anorthic system, space group P-1, a=1.12390 (4) nm, b=1.16868 (4) nm, c=
1.18171 (4) nm, α=67.6440 (10) °, β=85.4060 (10) °, γ=64.0140 (10) °, Z=1, V=
1.28335(8) nm3, Dc=1.463 Mg m-3, m (MoK α)=1.030 mm-1, F (000)=576.
Embodiment 3:
The preparation to tert-butyl benzoyl hydrazone stannous phenide coordination compound of the 2-carbonyl propionic acid:
0.344g (1.0mmol) diphenyl stannum dichloride, 0.202g is added in the 100mL there-necked flask having nitrogen to protect
(1.05mmol) to tert-butyl benzoyl hydrazine, 0.126g (1.15mmol) Sodium Pyruvate and 25mL solvent absolute methanol, in temperature
24 h are reacted under conditions of being 45 ~ 75 DEG C, cooling, filter, under conditions of 20 ~ 35 DEG C, control solvent volatilization crystallization, obtain yellow
Transparent crystal, is 2-carbonyl propionic acid to tert-butyl benzoyl hydrazone stannous phenide coordination compound.Productivity: 89.0%.Fusing point: 104 ~ 106
℃(dec)。
Elementary analysis (C54H60N4O8Sn2): value of calculation: C 57.37, H 5.35, N 4.96；Measured value: C 57.40, H
5.33, N 4.98.
FT-IR (KBr, ν/cm-1): 3631, 3072, 3055, 2962, 2904, 1689, 1602, 1492,
1479, 1431, 1390, 1363, 1321, 1267, 1203, 1159, 1070, 1001, 921, 848, 769,
723, 690, 594, 557, 543, 493, 453。
1H NMR (500 MHz, CDCl3, δ/ppm): 8.28 (d, J = 8.5 Hz, 2H), 7.81-7.83
(m, 4H), 7.55 (d, J = 8.4 Hz, 2H), 7.44-7.48 (m, 6H), 3.49 (s, 3H), 2.62 (s,
3H), 1.38 (s, 9H), 0.98 (s, 1H)。
13C NMR (126 MHz, CDCl3, δ/ppm): 174.83, 163.89, 158.74, 155.41,
136.15, 135.60, 131.42, 129.37, 129.31, 128.60, 125.54, 50.92, 35.19, 31.15,
13.95。
119Sn NMR (187 MHz, CDCl3, δ/ppm): -293.95。
Crystallographic data: anorthic system, space group P-1, a=1.12390 (4) nm, b=1.16868 (4) nm, c=
1.18171 (4) nm, α=67.6440 (10) °, β=85.4060 (10) °, γ=64.0140 (10) °, Z=1, V=
1.28335(8) nm3, Dc=1.463 Mg m-3, m (MoK α)=1.030 mm-1, F (000)=576.
Embodiment 4:
The preparation to tert-butyl benzoyl hydrazone stannous phenide coordination compound of the 2-carbonyl propionic acid:
3.440g (10.0mmol) diphenyl stannum dichloride, 1.978g is added in the 500mL there-necked flask having nitrogen to protect
(10.3mmol) to tert-butyl benzoyl hydrazine, 1.210g (11.0mmol) Sodium Pyruvate and 210mL solvent absolute methanol, in temperature
Degree reacts 22 h under conditions of being 45 ~ 75 DEG C, cooling, filters, and controls solvent volatilization crystallization, obtain yellow under conditions of 20 ~ 35 DEG C
Color transparent crystal, is 2-carbonyl propionic acid to tert-butyl benzoyl hydrazone stannous phenide coordination compound.Productivity: 82.3%.Fusing point: 104 ~
106℃(dec)。
Elementary analysis (C54H60N4O8Sn2): value of calculation: C 57.37, H 5.35, N 4.96；Measured value: C 57.40, H
5.33, N 4.98.
FT-IR (KBr, ν/cm-1): 3631, 3072, 3055, 2962, 2904, 1689, 1602, 1492,
1479, 1431, 1390, 1363, 1321, 1267, 1203, 1159, 1070, 1001, 921, 848, 769,
723, 690, 594, 557, 543, 493, 453。
1H NMR (500 MHz, CDCl3, δ/ppm): 8.28 (d, J = 8.5 Hz, 2H), 7.81-7.83
(m, 4H), 7.55 (d, J = 8.4 Hz, 2H), 7.44-7.48 (m, 6H), 3.49 (s, 3H), 2.62 (s,
3H), 1.38 (s, 9H), 0.98 (s, 1H)。
13C NMR (126 MHz, CDCl3, δ/ppm): 174.83, 163.89, 158.74, 155.41,
136.15, 135.60, 131.42, 129.37, 129.31, 128.60, 125.54, 50.92, 35.19, 31.15,
13.95。
119Sn NMR (187 MHz, CDCl3, δ/ppm): -293.95。
Crystallographic data: anorthic system, space group P-1, a=1.12390 (4) nm, b=1.16868 (4) nm, c=
1.18171 (4) nm, α=67.6440 (10) °, β=85.4060 (10) °, γ=64.0140 (10) °, Z=1, V=
1.28335(8) nm3, Dc=1.463 Mg m-3, m (MoK α)=1.030 mm-1, F (000)=576.
Test example:
The 2-carbonyl propionic acid of the present invention is to tert-butyl benzoyl hydrazone stannous phenide coordination compound, and it is to pass through that its Anticancer Activity in vitro measures
MTT experiment method realizes.
MTT analytic process:
With metabolism reduction 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide it is
Basis.Succinate dehydrogenase in living cells mitochondrion can make exogenous MTT be reduced to water-insoluble bluish violet crystallization first a ceremonial jade-ladle, used in libation
(Formazan) and be deposited in cell, and dead cell is without this function.Dimethyl sulfoxide (DMSO) can dissolve the first a ceremonial jade-ladle, used in libation in cell,
Measure the optical density of characteristic wavelength by microplate reader, can indirectly reflect living cells quantity.
Mtt assay is used to measure the 2-carbonyl propionic acid of embodiment 1 preparation to tert-butyl benzoyl hydrazone stannous phenide coordination compound
To human lung carcinoma cell (H460), human liver cancer cell (HepG2) and the inhibitory activity of human breast cancer cell (MCF7).
Cell strain and cultivating system: H460, HepG2 and MCF7 cell strain takes from American. tissue incubator (ATCC).With containing
RPMI 1640 (GIBICO company) culture medium of 10% hyclone, at 5% (volume fraction) CO2, 37 DEG C of saturated humidity incubators
Inside carry out In vitro culture.
Test process: test medicinal liquid (1nM ~ 10 μM) is added separately in each hole according to the Concentraton gradient of concentration, often
Individual concentration sets 6 parallel holes.Experiment is divided into drug study group (being separately added into the test medicine of variable concentrations), matched group (only to add training
Nutrient solution and cell, be not added with testing medicine) and blank group (only adding cultivation medicine, be not added with cell and test medicine).Orifice plate after dosing is put
In 37 DEG C, 5%CO2Incubator is cultivated 72h.The activity of control drug measures according to the method for test sample.Cultivating 72h
After orifice plate in, every hole adds MTT 40 μ L (being made into 4mg/mL with D-Hanks buffer).After placing 4h at 37 DEG C, remove upper strata
Clear liquid.Every hole adds 150 μ L DMSO, and vibrate 5min, makes Formazan crystallization dissolve.Finally, utilize automatic microplate reader at 570nm
The optical density in each hole is detected at wavelength.
Data process: data process and use Graph Pad Prism version 7.0 program, coordination compound IC50Pass through journey
The nonlinear regression model (NLRM) in sequence with S-shaped dose response is fitted obtaining.
Thin to human lung carcinoma cell (H460), human liver cancer cell (HepG2) and human breast cancer cell (MCF7) with MTT analytic process
Born of the same parents' strain is analyzed, and measures its IC50Value, result is as shown in table 1, and conclusion is: from data in table, with the 2-carbonyl of the present invention
Propanoic acid is used as cancer therapy drug to tert-butyl benzoyl hydrazone stannous phenide coordination compound, to human lung carcinoma cell (H460), human liver cancer cell
(HepG2) and human breast cancer cell (MCF7) has certain drug effect, can be as the candidate compound of cancer therapy drug.
Tert-butyl benzoyl hydrazone stannous phenide coordination compound cancer therapy drug external activity is tested data by table 1 2-carbonyl propionic acid.
| People's pulmonary carcinoma | People's hepatocarcinoma | Human breast carcinoma | |
| Cell strain | H460 | HepG2 | MCF7 |
| IC50(μM) | 4.06±0.26 | 1.46±0.75 | 1.75±0.67 |
2-carbonyl propionic acid prepared by remaining embodiment to tert-butyl benzoyl hydrazone stannous phenide coordination compound with mtt assay to people's lung
The same test example of active anticancer method of testing of cancerous cell (H460), human liver cancer cell (HepG2) and human breast cancer cell (MCF7),
Test result is essentially identical with table 1.
These are only the preferred embodiments of the present invention and test example, be not limited to the present invention, it is clear that the skill of this area
Art personnel can carry out various change, modification without departing from the spirit and scope of the present invention to the present invention.If to the present invention's
These amendments and modification belong within the scope of the claims in the present invention and equivalent technologies thereof, belong to the protection model of the present invention
Enclose.
Claims (9)
1. 2-carbonyl propionic acid is to a tert-butyl benzoyl hydrazone stannous phenide coordination compound, for the coordination compound of following structure formula (I):
(I)
Wherein Ph is phenyl.
2. the one 2-carbonyl propionic acid that contains as claimed in claim 1 is to tert-butyl benzoyl hydrazone stannous phenide coordination compound, and it is red
External spectrum data: FT-IR (KBr, ν/cm-1): 3631, 3072, 3055, 2962, 2904, 1689, 1602,
1492, 1479, 1431, 1390, 1363, 1321, 1267, 1203, 1159, 1070, 1001, 921, 848,
769, 723, 690, 594, 557, 543, 493, 453；Its nuclear-magnetism modal data:1H NMR (500 MHz, CDCl3, δ/
ppm): 8.28 (d, J = 8.5 Hz, 2H), 7.81-7.83 (m, 4H), 7.55 (d, J = 8.4 Hz, 2H),
7.44-7.48 (m, 6H), 3.49 (s, 3H), 2.62 (s, 3H), 1.38 (s, 9H), 0.98 (s, 1H)；13C
NMR (126 MHz, CDCl3, δ/ppm): 174.83, 163.89, 158.74, 155.41, 136.15, 135.60,
131.42, 129.37, 129.31, 128.60, 125.54, 50.92, 35.19, 31.15, 13.95；119Sn NMR
(187 MHz, CDCl3, δ/ppm): -293.95。
3. 2-carbonyl propionic acid as claimed in claim 1 is to tert-butyl benzoyl hydrazone stannous phenide coordination compound, wherein, described
2-carbonyl propionic acid is crystal structure to tert-butyl benzoyl hydrazone stannous phenide coordination compound, and its crystallographic data is as follows: anorthic system,
Space group P-1, a=1.12390 (4) nm, b=1.16868 (4) nm, c=1.18171 (4 nm, α=67.6440
° (10), β=85.4060 (10) °, γ=64.0140 (10) °, Z=1, V=1.28335 (8) nm3, Dc=1.463
Mg·m-3, m (MoK α)=1.030 mm-1, F (000)=576；In molecule, tin atom is seven coordination distortion pentagonal bipyramid configurations.
4. 2-carbonyl propionic acid described in claim 1 has certain thermally-stabilised model to tert-butyl benzoyl hydrazone stannous phenide coordination compound
Enclose, can stable existence below 104 DEG C.
5. the preparation method to tert-butyl benzoyl hydrazone stannous phenide coordination compound of the 2-carbonyl propionic acid described in claim 1, it is special
Levy is to add diphenyl stannum dichloride in the reaction vessel having nitrogen to protect, to tert-butyl benzoyl hydrazine, Sodium Pyruvate and molten
Agent absolute methanol, reacts 5 ~ 24 h, cooling under conditions of temperature is 45 ~ 75 DEG C, filters, control under conditions of 20 ~ 35 DEG C
Solvent volatilization crystallization, obtains yellow transparent crystal, is 2-carbonyl propionic acid to tert-butyl benzoyl hydrazone stannous phenide coordination compound.
6. the method for preparation as claimed in claim 5, it is characterised in that described diphenyl stannum dichloride, to tert-butyl benzene first
Hydrazides, Sodium Pyruvate three the amount of material than for 1:(1 ~ 1.05): (1.05 ~ 1.15).
7. the method for preparation as claimed in claim 5, it is characterised in that described solvent absolute methanol consumption is every mM two
Phenyl dichloro stannum adds 15 ~ and 35 milliliters.
8. 2-carbonyl propionic acid described in claim 1 to tert-butyl benzoyl hydrazone stannous phenide coordination compound in preparing cancer therapy drug
Application.
9. the application described in claim 8, wherein said cancerous cell is human lung carcinoma cell, human liver cancer cell, human breast cancer cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610712404.2A CN106317104A (en) | 2016-08-24 | 2016-08-24 | 2- carbonyl propionic acid p-tert-butyl benzoyl hydrazone stannous phenide complex and preparing method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610712404.2A CN106317104A (en) | 2016-08-24 | 2016-08-24 | 2- carbonyl propionic acid p-tert-butyl benzoyl hydrazone stannous phenide complex and preparing method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106317104A true CN106317104A (en) | 2017-01-11 |
Family
ID=57742456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610712404.2A Pending CN106317104A (en) | 2016-08-24 | 2016-08-24 | 2- carbonyl propionic acid p-tert-butyl benzoyl hydrazone stannous phenide complex and preparing method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106317104A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105777798A (en) * | 2016-04-23 | 2016-07-20 | 衡阳师范学院 | 2-carbonyl-2-phenylacetic acid para hydroxybenzene formyl hydrazone dibutyl tin complex as well as preparation method and application thereof |
-
2016
- 2016-08-24 CN CN201610712404.2A patent/CN106317104A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105777798A (en) * | 2016-04-23 | 2016-07-20 | 衡阳师范学院 | 2-carbonyl-2-phenylacetic acid para hydroxybenzene formyl hydrazone dibutyl tin complex as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 《INORGANICA CHIMICA ACTA》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106432323A (en) | 2-carbonyl butyric acid p-methoxy benzoyl hydrazone di-n-butyltin complex and preparation method and application thereof | |
| CN106366113A (en) | 2-oxo-propionic acid p-toluyl hydrazone di-2, 4-dichlorobenzyltin complex and its preparation method and use | |
| CN106336427A (en) | 2-carbonyl-2-phenyl acetic acid p-nitrobenzoylhydrazone bis(2,4-dichlorobenzyl)tin complex and preparation method and application thereof | |
| CN106220669B (en) | A kind of dialkyl tin complex of the ligand containing acylhydrazone and its preparation method and application | |
| CN106336430A (en) | 2-oxo-butyric acid p-methyl benzoyl hydrazone di-n-butyl tin complex and preparation method and application thereof | |
| CN106432322A (en) | 2-Carbonyl-2-phenylacetic acid p-nitrobenzoyl hydrazone diphenyltin complex, and preparation method and application thereof | |
| CN106317104A (en) | 2- carbonyl propionic acid p-tert-butyl benzoyl hydrazone stannous phenide complex and preparing method and application thereof | |
| CN106336429B (en) | A kind of ALPHA-ketobutyric acid is to toluyl hydrazone stannous phenide complex and its preparation method and application | |
| CN106220676B (en) | A kind of 2- carbonyl propionic acids are to methoxybenzoyl hydrazone Dibenzyltin complex and its preparation method and application | |
| CN106380480B (en) | A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide complex and its preparation method and application | |
| CN106220675A (en) | A kind of 2 carbonyl butanoic acid are to tert-butyl benzoyl hydrazone stannous phenide coordination compound and its preparation method and application | |
| CN106220677A (en) | A kind of 2 carbonyl butanoic acid are to toluyl hydrazone di-n-butyl tin coordination compound and its preparation method and application | |
| CN106317105A (en) | 2- carbonyl- 2- phenyl acetic acid p-nitro benzoyl hydrazone 2-n-butyl tin complex and preparing method and application thereof | |
| CN106279250A (en) | A kind of 2 carbonyl 3 phenylpropionic acid para hydroxybenzene formyl hydrazone stannous phenide coordination compounds and its preparation method and application | |
| CN106220673A (en) | A kind of 2 carbonyl 2 phenylacetic acids are to toluyl hydrazone di-n-butyl tin coordination compound and its preparation method and application | |
| CN106279258A (en) | A kind of 2 carbonyl butanoic acid salicyloyl hydrazone two (2,4 dichloro benzyl) stannum coordination compounds and its preparation method and application | |
| CN106220678A (en) | A kind of 2 carbonyl propionic acid p-nitrophenyl formyl hydrazones two are to methyl-benzyl stannum coordination compound and its preparation method and application | |
| CN106220671A (en) | A kind of 2 carbonyl 2 phenylacetic acids are to toluyl hydrazone stannous phenide coordination compound and its preparation method and application | |
| CN106243148A (en) | A kind of 2 carbonyl 2 phenylacetic acid benzoyl hydrazone stannous phenide coordination compounds and its preparation method and application | |
| CN106220674A (en) | A kind of 2 carbonyl butanoic acid salicyloyl hydrazone Dibenzyltin coordination compounds and its preparation method and application | |
| CN106279251A (en) | A kind of 2 carbonyl propionic acid benzoyl hydrazones two are to methyl-benzyl stannum coordination compound and its preparation method and application | |
| CN106279261A (en) | A kind of 2 carbonyl 3 phenylpropionic acids are to toluyl hydrazone di-n-butyl tin coordination compound and its preparation method and application | |
| CN106220670A (en) | A kind of 2 carbonyl 3 phenylpropionic acid p-nitrophenyl formyl hydrazones two are to methyl-benzyl stannum coordination compound and its preparation method and application | |
| CN106220672A (en) | A kind of 2 carbonyl 2 phenylacetic acids are to tert-butyl benzoyl hydrazone di-n-butyl tin coordination compound and its preparation method and application | |
| CN106317103A (en) | 2-carbonyl butyrate p-hydroxy benzoyl hydrazone di-n-butyltin complex and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170111 |
|
| WD01 | Invention patent application deemed withdrawn after publication |